Translating tumor antigens into cancer vaccines

Clinical and Vaccine Immunology

Volumn 18, Issue 1, 2011, Pages 23-34

  Buonaguro, Luigi ^a,b   Petrizzo, Annacarmen ^a   Tornesello, Maria Lina ^a   Buonaguro, Franco M ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA ACTIN; BETA CATENIN; CANCER ANTIBODY; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; DENDRITIC CELL VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GANGLIOSIDE GD2; GANGLIOSIDE GD3; GANGLIOSIDE GM2; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN 70; HLA A2 ANTIGEN; IMMUNOLOGICAL ADJUVANT; LIVIN; MELANOMA ANTIGEN; MONOPHENOL MONOOXYGENASE; MUCIN 1; MYOSIN; PEPTIDE VACCINE; PROSTATE SPECIFIC ANTIGEN; PROTEIN P53; SURVIVIN; TUMOR ANTIGEN; TUMOR CELL VACCINE; UNINDEXED DRUG; VITESPEN; WT1 PROTEIN;

ACTIVE IMMUNIZATION; ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN PRESENTING CELL; B CELL LYMPHOMA; BREAST TUMOR; CANCER CELL; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COLORECTAL CANCER; COLORECTAL TUMOR; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGICAL TOLERANCE; KIDNEY CARCINOMA; LIVER TUMOR; LUNG TUMOR; MACROPHAGE; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHODGKIN LYMPHOMA; NONHUMAN; ONCOGENE NEU; OVARY TUMOR; PANCREAS TUMOR; PASSIVE IMMUNIZATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SHORT SURVEY; TH17 CELL; UTERUS TUMOR;

ANTIGENS, NEOPLASM; CANCER VACCINES; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; NEOPLASMS; VACCINATION;

EID: 78650919399     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00286-10     Document Type: Short Survey

References (203)

1. Ayyoub, M., S. Stevanovic, U. Sahin, P. Guillaume, C. Servis, D. Rimoldi, D. Valmori, P. Romero, J. C. Cerottini, H. G. Rammensee, M. Pfreundschuh, D. Speiser, and F. Levy. 2002. Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma. J. Immunol. 168:1717-1722. (Pubitemid 34135769)
2. Azuma, K., S. Shichijo, Y. Maeda, T. Nakatsura, Y. Nonaka, T. Fujii, K. Koike, and K. Itoh. 2003. Mutated p53 gene encodes a nonmutated epitope recognized by HLA-B*4601-restricted and tumor cell-reactive CTLs at tumor site. Cancer Res. 63:854-858.
3. Baars, A., A. M. Claessen, A. J. van den Eertwegh, H. E. Gall, A. G. Stam, S. Meijer, G. Giaccone, C. J. Meijer, R. J. Scheper, J. Wagstaff, J. B. Vermorken, and H. M. Pinedo. 2000. Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: experience in 81 patients. Ann. Oncol. 11:965-970.
4. Bakker, A. B., M. W. Schreurs, A. J. de Boer, Y. Kawakami, S. A. Rosenberg, G. J. Adema, and C. G. Figdor. 1994. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J. Exp. Med. 179:1005-1009.
5. Banchereau, J., and A. K. Palucka. 2005. Dendritic cells as therapeutic vaccines against cancer. Nat. Rev. Immunol. 5:296-306.
6. Bay, S., S. Fort, L. Birikaki, C. Ganneau, E. Samain, Y. M. Coic, F. Bonhomme, E. Deriaud, C. Leclerc, and R. Lo-Man. 2009. Induction of a melanoma-specific antibody response by a monovalent, but not a divalent, synthetic GM2 neoglycopeptide. ChemMedChem 4:582-587.
7. Belli, F., A. Testori, L. Rivoltini, M. Maio, G. Andreola, M. R. Sertoli, G. Gallino, A. Piris, A. Cattelan, I. Lazzari, M. Carrabba, G. Scita, C. Santantonio, L. Pilla, G. Tragni, C. Lombardo, F. Arienti, A. Marchiano, P. Queirolo, F. Bertolini, A. Cova, E. Lamaj, L. Ascani, R. Camerini, M. Corsi, N. Cascinelli, J. J. Lewis, P. Srivastava, and G. Parmiani. 2002. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J. Clin. Oncol. 20:4169-4180.
8. Bendandi, M. 2009. Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures. Nat. Rev. Cancer 9:675-681.
9. Bennett, S. R., F. R. Carbone, F. Karamalis, R. A. Flavell, J. F. Miller, and W. R. Heath. 1998. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393:478-480.
10. Berard, F., P. Blanco, J. Davoust, E. M. Neidhart-Berard, M. Nouri-Shirazi, N. Taquet, D. Rimoldi, J. C. Cerottini, J. Banchereau, and A. K. Palucka. 2000. Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J. Exp. Med. 192:1535-1544.
11. + suppressor-inducer T-cells. Cancer Res. 48:1671-1675.
12. Berd, D., T. Sato, H. C. Maguire, Jr., J. Kairys, and M. J. Mastrangelo. 2004. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J. Clin. Oncol. 22:403-415.
13. + T cell epitopes. Cancer Immunol. Immunother. 58:187-200.
14. Bijker, M. S., S. J. van den Eeden, K. L. Franken, C. J. Melief, S. H. van der Burg, and R. Offringa. 2008. Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation. Eur. J. Immunol. 38:1033-1042.
15. Bolhassani, A., and S. Rafati. 2008. Heat-shock proteins as powerful weapons in vaccine development. Expert Rev. Vaccines 7:1185-1199.
16. Borbulevych, O. Y., T. K. Baxter, Z. Yu, N. P. Restifo, and B. M. Baker. 2005. Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: implications for vaccine design. J. Immunol. 174:4812-4820.
17. Brandau, S., and H. Suttmann. 2007. Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement. Biomed. Pharmacother. 61:299-305.
18. Buonaguro, L., A. Petrizzo, M. Tornesello, M. Napolitano, D. Martorelli, G. Castello, G. Beneduce, R. A. De, O. Perrella, L. Romagnoli, V. Sousa, R. De, V. R. Dolcetti, and F. M. Buonaguro. 2010. Immune signatures in human PBMCs of idiotypic vaccine for HCV-related lymphoproliferative disorders. J. Transl. Med. 8:18.
19. Burnet, F. M. 1970. The concept of immunological surveillance. Prog. Exp. Tumor Res. 13:1-27.
20. Burnet, M. 1957. Cancer: a biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications. Br. Med. J. 1:841-847.
21. Burnet, M. 1957. Cancer: a biological approach. I. The processes of control. Br. Med. J. 1:779-786.
22. Buskas, T., S. Ingale, and G. J. Boons. 2005. Towards a fully synthetic carbohydrate-based anticancer vaccine: synthesis and immunological evaluation of a lipidated glycopeptide containing the tumor-associated tn antigen. Angew. Chem. Int. Ed. Engl. 44:5985-5988.
23. Butterfield, L. H., A. Ribas, V. B. Dissette, S. N. Amarnani, H. T. Vu, D. Oseguera, H. J. Wang, R. M. Elashoff, W. H. McBride, B. Mukherji, A. J. Cochran, J. A. Glaspy, and J. S. Economou. 2003. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin. Cancer Res. 9:998-1008.
24. Celluzzi, C. M., J. I. Mayordomo, W. J. Storkus, M. T. Lotze, and L. D. Falo, Jr. 1996. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J. Exp. Med. 183:283-287.
25. Cerami, E., E. Demir, N. Schultz, B. S. Taylor, and C. Sander. 2010. Automated network analysis identifies core pathways in glioblastoma. PLoS One 5:e8918.
26. Chan, L., N. Hardwick, D. Darling, J. Galea-Lauri, J. Gaken, S. Devereux, M. Kemeny, G. Mufti, and F. Farzaneh. 2005. IL-2/B7.1 (CD80) fusagene transduction of AML blasts by a self-inactivating lentiviral vector stimulates T cell responses in vitro: a strategy to generate whole cell vaccines for AML. Mol. Ther. 11:120-131.
27. Chapman, P. B., D. M. Morrissey, K. S. Panageas, W. B. Hamilton, C. Zhan, A. N. Destro, L. Williams, R. J. Israel, and P. O. Livingston. 2000. Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: a dose-response study. Clin. Cancer Res. 6:874-879.
28. Charles, E. D., R. M. Green, S. Marukian, A. H. Talal, G. V. Lake-Bakaar, I. M. Jacobson, C. M. Rice, and L. B. Dustin. 2008. Clonal expansion of immunoglobulin M+CD27+ B cells in HCV-associated mixed cryoglobulinemia. Blood 111:1344-1356.
29. Chaudhuri, D., R. Suriano, A. Mittelman, and R. K. Tiwari. 2009. Targeting the immune system in cancer. Curr. Pharm. Biotechnol. 10:166-184.
30. Chaux, P., R. Luiten, N. Demotte, V. Vantomme, V. Stroobant, C. Traversari, V. Russo, E. Schultz, G. R. Cornelis, T. Boon, and B. P. van der. 1999. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1. J. Immunol. 163:2928-2936.
31. Cheuk, A. T., J. W. Wells, L. Chan, N. B. Westwood, S. A. Berger, H. Yagita, K. Okumura, F. Farzaneh, G. J. Mufti, and B. A. Guinn. 2009. Anti-tumor immunity in a model of acute myeloid leukemia. Leuk. Lymphoma 50:447-454.
32. Chiang, C. L., F. Benencia, and G. Coukos. 2010. Whole tumor antigen vaccines. Semin. Immunol.
33. Chu, N. R., H. B. Wu, T. Wu, L. J. Boux, M. I. Siegel, and L. A. Mizzen. 2000. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guerin (BCG) hsp65 and HPV16 E7. Clin. Exp. Immunol. 121:216-225.
34. Clive, K. S., J. A. Tyler, G. T. Clifton, J. P. Holmes, E. A. Mittendorf, S. Ponniah, and G. E. Peoples. 2010. Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental? Expert Rev. Vaccines 9:519-525.
35. Colella, T. A., T. N. Bullock, L. B. Russell, D. W. Mullins, W. W. Overwijk, C. J. Luckey, R. A. Pierce, N. P. Restifo, and V. H. Engelhard. 2000. Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy. J. Exp. Med. 191:1221-1232.
36. Conroy, H., N. A. Marshall, and K. H. Mills. 2008. TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours. Oncogene 27:168-180.
37. Corman, J. M., E. E. Sercarz, and N. K. Nanda. 1998. Recognition of prostate-specific antigenic peptide determinants by human CD4 and CD8 T cells. Clin. Exp. Immunol. 114:166-172.
38. Correale, P., K. Walmsley, C. Nieroda, S. Zaremba, M. Zhu, J. Schlom, and K. Y. Tsang. 1997. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J. Natl. Cancer Inst. 89:293-300.
39. Crawford, F., E. Huseby, J. White, P. Marrack, and J. W. Kappler. 2004. Mimotopes for alloreactive and conventional T cells in a peptide-MHC display library. PLoS Biol. 2:E90.
40. Crellin, N. K., R. V. Garcia, O. Hadisfar, S. E. Allan, T. S. Steiner, and M. K. Levings. 2005. Human CD4+ T cells express TLR5 and its ligand flagellin enhances the suppressive capacity and expression of FOXP3 in CD4+CD25+ T regulatory cells. J. Immunol. 175:8051-8059.
41. Dannull, J., Z. Su, D. Rizzieri, B. K. Yang, D. Coleman, D. Yancey, A. Zhang, P. Dahm, N. Chao, E. Gilboa, and J. Vieweg. 2005. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. 115:3623-3633.
42. Dennis, J. W., M. Granovsky, and C. E. Warren. 1999. Glycoprotein glycosylation and cancer progression. Biochim. Biophys. Acta 1473:21-34.
43. De Re, V., S. De Vita, A. Marzotto, M. Rupolo, A. Gloghini, B. Pivetta, D. Gasparotto, A. Carbone, and M. Boiocchi. 2000. Sequence analysis of the immunoglobulin antigen receptor of hepatitis C virus-associated non-Hodgkin lymphomas suggests that the malignant cells are derived from the rheumatoid factor-producing cells that occur mainly in type II cryoglobulinemia. Blood 96:3578-3584.
44. de Re, V., M. P. Simula, A. Pavan, M. Garziera, D. Marin, R. Dolcetti, V. S. De, D. Sansonno, S. Geremia, and G. Toffoli. 2009. Characterization of antibodies directed against the immunoglobulin light kappa chain variable chain region (VK) of hepatitis C virus-related type-II mixed cryoglobulinemia and B-cell proliferations. Ann. N. Y. Acad. Sci. 1173:152-160.
45. De Smet, C., C. Lurquin, B. Lethe, V. Martelange, and T. Boon. 1999. DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol. Cell. Biol. 19:7327-7335.
46. De Smet, C., C. Lurquin, B. P. van der, P. E. De, F. Brasseur, and T. Boon. 1994. Sequence and expression pattern of the human MAGE2 gene. Immunogenetics 39:121-129. (Pubitemid 23344813)
47. de Visser, K. E., T. A. Cordaro, H. W. Kessels, F. H. Tirion, T. N. Schumacher, and A. M. Kruisbeek. 2001. Low-avidity self-specific T cells display a pronounced expansion defect that can be overcome by altered peptide ligands. J. Immunol. 167:3818-3828.
48. Ding, L., G. Getz, D. A. Wheeler, E. R. Mardis, M. D. McLellan, K. Cibulskis, C. Sougnez, H. Greulich, D. M. Muzny, M. B. Morgan, L. Fulton, R. S. Fulton, Q. Zhang, M. C. Wendl, M. S. Lawrence, D. E. Larson, K. Chen, D. J. Dooling, A. Sabo, A. C. Hawes, H. Shen, S. N. Jhangiani, L. R. Lewis, O. Hall, Y. Zhu, T. Mathew, Y. Ren, J. Yao, S. E. Scherer, K. Clerc, G. A. Metcalf, B. Ng, A. Milosavljevic, M. L. Gonzalez-Garay, J. R. Osborne, R. Meyer, X. Shi, Y. Tang, D. C. Koboldt, L. Lin, R. Abbott, T. L. Miner, C. Pohl, G. Fewell, C. Haipek, H. Schmidt, B. H. Dunford-Shore, A. Kraja, S. D. Crosby, C. S. Sawyer, T. Vickery, S. Sander, J. Robinson, W. Winckler, J. Baldwin, L. R. Chirieac, A. Dutt, T. Fennell, M. Hanna, B. E. Johnson, R. C. Onofrio, R. K. Thomas, G. Tonon, B. A. Weir, X. Zhao, L. Ziaugra, M. C. Zody, T. Giordano, M. B. Orringer, J. A. Roth, M. R. Spitz, I. I. Wistuba, B. Ozenberger, P. J. Good, A. C. Chang, D. G. Beer, M. A. Watson, M. Ladanyi, S. Broderick, A. Yoshizawa, W. D. Travis, W. Pao, M. A. Province, G. M. Weinstock, H. E. Varmus, S. B. Gabriel, E. S. Lander, R. A. Gibbs, M. Meyerson, and R. K. Wilson. 2008. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455:1069-1075.
49. Disis, M. L., T. A. Gooley, K. Rinn, D. Davis, M. Piepkorn, M. A. Cheever, K. L. Knutson, and K. Schiffman. 2002. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J. Clin. Oncol. 20:2624-2632.
50. Dranoff, G. 2002. GM-CSF-based cancer vaccines. Immunol. Rev. 188:147-154.
51. Dranoff, G., E. Jaffee, A. Lazenby, P. Golumbek, H. Levitsky, K. Brose, V. Jackson, H. Hamada, D. Pardoll, and R. C. Mulligan. 1993. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and longlasting anti-tumor immunity. Proc. Natl. Acad. Sci. U. S. A. 90:3539-3543.
52. + T cells to differentiate into CTL. Eur. J. Immunol. 37:1678-1690.
53. Dunn, G. P., A. T. Bruce, H. Ikeda, L. J. Old, and R. D. Schreiber. 2002. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3:991-998.
54. Dunn, G. P., L. J. Old, and R. D. Schreiber. 2004. The three Es of cancer immunoediting. Annu. Rev. Immunol. 22:329-360.
55. Einstein, M. H., A. S. Kadish, R. D. Burk, M. Y. Kim, S. Wadler, H. Streicher, G. L. Goldberg, and C. D. Runowicz. 2007. Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III. Gynecol. Oncol. 106:453-460.
56. Emadi, A., R. J. Jones, and R. A. Brodsky. 2009. Cyclophosphamide and cancer: golden anniversary. Nat. Rev. Clin. Oncol. 6:638-647.
57. Emens, L. A. 2009. GM-CSF-secreting vaccines for solid tumors. Curr. Opin. Invest. Drugs. 10:1315-1324.
58. Fox, E. J., J. J. Salk, and L. A. Loeb. 2009. Cancer genome sequencing - an interim analysis. Cancer Res. 69:4948-4950.
59. Futreal, P. A., L. Coin, M. Marshall, T. Down, T. Hubbard, R. Wooster, N. Rahman, and M. R. Stratton. 2004. A census of human cancer genes. Nat. Rev. Cancer 4:177-183.
60. + T cells. Curr. Opin. Immunol. 15:690-696.
61. Gilboa, E. 1999. The makings of a tumor rejection antigen. Immunity 11:263-270.
62. Gong, J., N. Nikrui, D. Chen, S. Koido, Z. Wu, Y. Tanaka, S. Cannistra, D. Avigan, and D. Kufe. 2000. Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J. Immunol. 165:1705-1711. (Pubitemid 30604610)
63. Greenman, C., P. Stephens, R. Smith, G. L. Dalgliesh, C. Hunter, G. Bignell, H. Davies, J. Teague, A. Butler, C. Stevens, S. Edkins, S. O'Meara, I. Vastrik, E. E. Schmidt, T. Avis, S. Barthorpe, G. Bhamra, G. Buck, B. Choudhury, J. Clements, J. Cole, E. Dicks, S. Forbes, K. Gray, K. Halliday, R. Harrison, K. Hills, J. Hinton, A. Jenkinson, D. Jones, A. Menzies, T. Mironenko, J. Perry, K. Raine, D. Richardson, R. Shepherd, A. Small, C. Tofts, J. Varian, T. Webb, S. West, S. Widaa, A. Yates, D. P. Cahill, D. N. Louis, P. Goldstraw, A. G. Nicholson, F. Brasseur, L. Looijenga, B. L. Weber, Y. E. Chiew, A. DeFazio, M. F. Greaves, A. R. Green, P. Campbell, E. Birney, D. F. Easton, G. Chenevix-Trench, M. H. Tan, S. K. Khoo, B. T. Teh, S. T. Yuen, S. Y. Leung, R. Wooster, P. A. Futreal, and M. R. Stratton. 2007. Patterns of somatic mutation in human cancer genomes. Nature 446:153-158.
64. Guo, Z., and Q. Wang. 2009. Recent development in carbohydrate-based cancer vaccines. Curr. Opin. Chem. Biol. 13:608-617.
65. Hakomori, S. 2001. Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Adv. Exp. Med. Biol. 491:369-402.
66. Hanahan, D., and R. A. Weinberg. 2000. The hallmarks of cancer. Cell 100:57-70.
67. Harris, J. E., L. Ryan, H. C. Hoover, Jr., R. K. Stuart, M. M. Oken, A. B. Benson III, E. Mansour, D. G. Haller, J. Manola, and M. G. Hanna, Jr. 2000. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J. Clin. Oncol. 18:148-157.
68. Hernandez, P., J. Huerta-Cepas, D. Montaner, F. Al-Shahrour, J. Valls, L. Gomez, G. Capella, J. Dopazo, and M. A. Pujana. 2007. Evidence for systems-level molecular mechanisms of tumorigenesis. BMC Genomics 8:185.
69. Hewitt, H. B., E. R. Blake, and A. S. Walder. 1976. A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. Br. J. Cancer 33:241-259.
70. Higano, C. S., P. F. Schellhammer, E. J. Small, P. A. Burch, J. Nemunaitis, L. Yuh, N. Provost, and M. W. Frohlich. 2009. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115:3670-3679.
71. Hiranuma, K., S. Tamaki, Y. Nishimura, S. Kusuki, M. Isogawa, G. Kim, M. Kaito, K. Kuribayashi, Y. Adachi, and Y. Yasutomi. 1999. Helper T cell determinant peptide contributes to induction of cellular immune responses by peptide vaccines against hepatitis C virus. J. Gen. Virol. 80(Pt. 1):187-193.
72. Hoffmann, T. K., D. J. Loftus, K. Nakano, M. J. Maeurer, K. Chikamatsu, E. Appella, T. L. Whiteside, and A. B. DeLeo. 2002. The ability of variant peptides to reverse the nonresponsiveness of T lymphocytes to the wild-type sequence p53(264-272) epitope. J. Immunol. 168:1338-1347.
73. Holmberg, L. A., and B. M. Sandmaier. 2004. Vaccination with Theratope (STn-KLH) as treatment for breast cancer. Expert Rev. Vaccines 3:655-663.
74. + T cell repertoires primed with agonist and native peptides derived from a tumor-associated antigen. J. Immunol. 180:1526-1534.
75. Ichihara, F., K. Kono, A. Takahashi, H. Kawaida, H. Sugai, and H. Fujii. 2003. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin. Cancer Res. 9:4404-4408.
76. Ingale, S., M. A. Wolfert, T. Buskas, and G. J. Boons. 2009. Increasing the antigenicity of synthetic tumor-associated carbohydrate antigens by targeting Toll-like receptors. Chembiochem 10:455-463.
77. Jacobs, J. F., C. J. Punt, W. J. Lesterhuis, R. P. Sutmuller, H. M. Brouwer, N. M. Scharenborg, I. S. Klasen, L. B. Hilbrands, C. G. Figdor, I. J. de Vries, and G. J. Adema. 2010. Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients. Clin. Cancer Res. 16:5067-5078.
78. Jager, E., Y. T. Chen, J. W. Drijfhout, J. Karbach, M. Ringhoffer, D. Jager, M. Arand, H. Wada, Y. Noguchi, E. Stockert, L. J. Old, and A. Knuth. 1998. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J. Exp. Med. 187:265-270.
79. + T cell epitopes derived from mammaglobin-A, a tumor-associated antigen of human breast cancer. Int. J. Cancer 102:499-506.
80. Jennings, H. J., and R. K. Sood. 1994. Synthetic glycoconjugates as human vaccines, p. 325-371. In Y. C. Lee and R. T. Lee (ed.), Neoglycoconjugates: preparation and applications. Academic Press, San Diego, CA.
81. Jinushi, M., F. S. Hodi, and G. Dranoff. 2008. Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines. Immunol. Rev. 222:287-298.
82. Jonasch, E., C. Wood, P. Tamboli, L. C. Pagliaro, S. M. Tu, J. Kim, P. Srivastava, C. Perez, L. Isakov, and N. Tannir. 2008. Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings. Br. J. Cancer. 98:1336-1341.
83. Jones, S., X. Zhang, D. W. Parsons, J. C. Lin, R. J. Leary, P. Angenendt, P. Mankoo, H. Carter, H. Kamiyama, A. Jimeno, S. M. Hong, B. Fu, M. T. Lin, E. S. Calhoun, M. Kamiyama, K. Walter, T. Nikolskaya, Y. Nikolsky, J. Hartigan, D. R. Smith, M. Hidalgo, S. D. Leach, A. P. Klein, E. M. Jaffee, M. Goggins, A. Maitra, C. Iacobuzio-Donahue, J. R. Eshleman, S. E. Kern, R. H. Hruban, R. Karchin, N. Papadopoulos, G. Parmigiani, B. Vogelstein, V. E. Velculescu, and K. W. Kinzler. 2008. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321:1801-1806.
84. Jordan, K. R., R. H. McMahan, C. B. Kemmler, J. W. Kappler, and J. E. Slansky. 2010. Peptide vaccines prevent tumor growth by activating T cells that respond to native tumor antigens. Proc. Natl. Acad. Sci. U. S. A. 107:4652-4657.
85. Junnila, S., A. Kokkola, M. L. Karjalainen-Lindsberg, P. Puolakkainen, and O. Monni. 2010. Genome-wide gene copy number and expression analysis of primary gastric tumors and gastric cancer cell lines. BMC Cancer 10:73.
86. Kagan, E., G. Ragupathi, S. S. Yi, C. A. Reis, J. Gildersleeve, D. Kahne, H. Clausen, S. J. Danishefsky, and P. O. Livingston. 2005. Comparison of antigen constructs and carrier molecules for augmenting the immunogenicity of the monosaccharide epithelial cancer antigen Tn. Cancer Immunol. Immunother. 54:424-430.
87. Kalinski, P., C. M. Hilkens, A. Snijders, F. G. Snijdewint, and M. L. Kapsenberg. 1997. IL-12-deficient dendritic cells, generated in the presence of prostaglandin E2, promote type 2 cytokine production in maturing human naive T helper cells. J. Immunol. 159:28-35.
88. Kalinski, P., P. L. Vieira, J. H. Schuitemaker, E. C. de Jong, and M. L. Kapsenberg. 2001. Prostaglandin E(2) is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer. Blood 97:3466-3469.
89. Kawakami, Y., S. Eliyahu, C. Jennings, K. Sakaguchi, X. Kang, S. Southwood, P. F. Robbins, A. Sette, E. Appella, and S. A. Rosenberg. 1995. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J. Immunol. 154:3961-3968.
90. Kawakami, Y., S. Eliyahu, K. Sakaguchi, P. F. Robbins, L. Rivoltini, J. R. Yannelli, E. Appella, and S. A. Rosenberg. 1994. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. 180:347-352.
91. Kawakami, Y., P. F. Robbins, X. Wang, J. P. Tupesis, M. R. Parkhurst, X. Kang, K. Sakaguchi, E. Appella, and S. A. Rosenberg. 1998. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles. J. Immunol. 161:6985-6992.
92. Kelly, D. F., E. R. Moxon, and A. J. Pollard. 2004. Haemophilus influenzae type b conjugate vaccines. Immunology 113:163-174.
93. Kenter, G. G., M. J. Welters, A. R. Valentijn, M. J. Lowik, D. M. Berendsvan der Meer, A. P. Vloon, J. W. Drijfhout, A. R. Wafelman, J. Oostendorp, G. J. Fleuren, R. Offringa, S. H. van der Burg, and C. J. Melief. 2008. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin. Cancer Res. 14:169-177.
94. Kirkwood, J. M., M. H. Strawderman, M. S. Ernstoff, T. J. Smith, E. C. Borden, and R. H. Blum. 1996. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J. Clin. Oncol. 14:7-17.
95. Knutson, K. L., K. Schiffman, and M. L. Disis. 2001. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J. Clin. Invest. 107:477-484.
96. Koido, S., E. Hara, S. Homma, Y. Namiki, T. Ohkusa, J. Gong, and H. Tajiri. 2009. Cancer vaccine by fusions of dendritic and cancer cells. Clin. Dev. Immunol. 2009:657369.
97. Koido, S., E. Hara, S. Homma, A. Torii, Y. Toyama, H. Kawahara, M. Watanabe, K. Yanaga, K. Fujise, H. Tajiri, J. Gong, and G. Toda. 2005. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells. Clin. Cancer Res. 11:7891-7900.
98. Koido, S., Y. Tanaka, H. Tajiri, and J. Gong. 2007. Generation and functional assessment of antigen-specific T cells stimulated by fusions of dendritic cells and allogeneic breast cancer cells. Vaccine 25:2610-2619.
99. Koski, G. K., P. A. Cohen, R. E. Roses, S. Xu, and B. J. Czerniecki. 2008. Reengineering dendritic cell-based anti-cancer vaccines. Immunol. Rev. 222:256-276.
100. Krieg, A. M. 2006. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. 5:471-484.
101. Krieg, A. M. 2008. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 27:161-167.
102. + T-cell responses to the tumor-specific antigen NY-ESO-1. J. Immunother. 28:252-257.
103. Lesterhuis, W. J., I. J. de Vries, G. J. Adema, and C. J. Punt. 2004. Dendritic cell-based vaccines in cancer immunotherapy: an update on clinical and immunological results. Ann. Oncol. 15(Suppl. 4):iv145-iv151.
104. Li, C. Y., Q. Huang, and H. F. Kung. 2005. Cytokine and immuno-gene therapy for solid tumors. Cell. Mol. Immunol. 2:81-91.
105. Lindquist, S., and E. A. Craig. 1988. The heat-shock proteins. Annu. Rev. Genet. 22:631-677.
106. Livingston, P. O. 1995. Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines. Immunol. Rev. 145:147-166.
107. Liyanage, U. K., T. T. Moore, H. G. Joo, Y. Tanaka, V. Herrmann, G. Doherty, J. A. Drebin, S. M. Strasberg, T. J. Eberlein, P. S. Goedegebuure, and D. C. Linehan. 2002. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 169:2756-2761.
108. Mahnke, K., K. Schonfeld, S. Fondel, S. Ring, S. Karakhanova, K. Wiedemeyer, T. Bedke, T. S. Johnson, V. Storn, S. Schallenberg, and A. H. Enk. 2007. Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int. J. Cancer 120:2723-2733.
109. Mailliard, R. B., A. Wankowicz-Kalinska, Q. Cai, A. Wesa, C. M. Hilkens, M. L. Kapsenberg, J. M. Kirkwood, W. J. Storkus, and P. Kalinski. 2004. Alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res. 64:5934-5937.
110. Mazzaferro, V., J. Coppa, M. G. Carrabba, L. Rivoltini, M. Schiavo, E. Regalia, L. Mariani, T. Camerini, A. Marchiano, S. Andreola, R. Camerini, M. Corsi, J. J. Lewis, P. K. Srivastava, and G. Parmiani. 2003. Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin. Cancer Res. 9:3235-3245.
111. McMahan, R. H., J. A. McWilliams, K. R. Jordan, S. W. Dow, D. B. Wilson, and J. E. Slansky. 2006. Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines. J. Clin. Invest. 116:2543-2551.
112. McWilliams, J. A., R. T. Sullivan, K. R. Jordan, R. H. McMahan, C. B. Kemmler, M. McDuffie, and J. E. Slansky. 2008. Age-dependent tolerance to an endogenous tumor-associated antigen. Vaccine 26:1863-1873.
113. Melief, C. J., and S. H. van der Burg. 2008. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat. Rev. Cancer 8:351-360.
114. Michael, A., G. Ball, N. Quatan, F. Wushishi, N. Russell, J. Whelan, P. Chakraborty, D. Leader, M. Whelan, and H. Pandha. 2005. Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables. Clin. Cancer Res. 11:4469-4478.
115. Mills, K. H. 2009. Designer adjuvants for enhancing the efficacy of infectious disease and cancer vaccines based on suppression of regulatory T cell induction. Immunol. Lett. 122:108-111.
116. Minev, B., J. Hipp, H. Firat, J. D. Schmidt, P. Langlade-Demoyen, and M. Zanetti. 2000. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc. Natl. Acad. Sci. U. S. A. 97:4796-4801.
117. Minev, B. R., F. L. Chavez, and M. S. Mitchell. 1999. Cancer vaccines: novel approaches and new promise. Pharmacol. Ther. 81:121-139.
118. Morse, M. A., A. C. Hobeika, T. Osada, D. Serra, D. Niedzwiecki, H. K. Lyerly, and T. M. Clay. 2008. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 112:610-618.
119. Murshid, A., J. Gong, and S. K. Calderwood. 2008. Heat-shock proteins in cancer vaccines: agents of antigen cross-presentation. Expert Rev. Vaccines 7:1019-1030.
120. Nava-Parada, P., G. Forni, K. L. Knutson, L. R. Pease, and E. Celis. 2007. Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors. Cancer Res. 67:1326-1334. (Pubitemid 46270793)
121. Nestle, F. O., S. Alijagic, M. Gilliet, Y. Sun, S. Grabbe, R. Dummer, G. Burg, and D. Schadendorf. 1998. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4:328-332.
122. + helper T cell responses in cancer patients. Blood 106:1008-1011.
123. Nizar, S., J. Copier, B. Meyer, M. Bodman-Smith, C. Galustian, D. Kumar, and A. Dalgleish. 2009. T-regulatory cell modulation: the future of cancer immunotherapy? Br. J. Cancer 100:1697-1703.
124. North, R. J. 1984. The murine antitumor immune response and its therapeutic manipulation. Adv. Immunol. 35:89-155.
125. Novellino, L., C. Castelli, and G. Parmiani. 2005. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol. Immunother. 54:187-207.
126. Osada, T., T. M. Clay, C. Y. Woo, M. A. Morse, and H. K. Lyerly. 2006. Dendritic cell-based immunotherapy. Int. Rev. Immunol. 25:377-413.
127. Overwijk, W. W., A. Tsung, K. R. Irvine, M. R. Parkhurst, T. J. Goletz, K. Tsung, M. W. Carroll, C. Liu, B. Moss, S. A. Rosenberg, and N. P. Restifo. 1998. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J. Exp. Med. 188:277-286.
128. Pace, L., S. Vitale, B. Dettori, C. Palombi, S. La, V. F. Belardelli, E. Proietti, and G. Doria. 2010. APC activation by IFN-alpha decreases regulatory T cell and enhances Th cell functions. J. Immunol. 184:5969-5979.
129. + T-cell immunity. J. Immunother. 29:545-557.
130. Pardoll, D. M. 1999. Inducing autoimmune disease to treat cancer. Proc. Natl. Acad. Sci. U. S. A. 96:5340-5342.
131. Parkhurst, M. R., E. B. Fitzgerald, S. Southwood, A. Sette, S. A. Rosenberg, and Y. Kawakami. 1998. Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer Res. 58:4895-4901.
132. Parmiani, G., C. Castelli, P. Dalerba, R. Mortarini, L. Rivoltini, F. M. Marincola, and A. Anichini. 2002. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J. Natl. Cancer Inst. 94:805-818.
133. Parmiani, G., F. A. De, L. Novellino, and C. Castelli. 2007. Unique human tumor antigens: immunobiology and use in clinical trials. J. Immunol. 178:1975-1979.
134. Parsons, D. W., S. Jones, X. Zhang, J. C. Lin, R. J. Leary, P. Angenendt,
135. Pehamberger, H., H. P. Soyer, A. Steiner, R. Kofler, M. Binder, P. Mischer, W. Pachinger, J. Aubock, P. Fritsch, H. Kerl, and K. Wolff. 1998. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J. Clin. Oncol. 16:1425-1429.
136. Perez, S. A., E. von Hofe, N. L. Kallinteris, A. D. Gritzapis, G. E. Peoples, M. Papamichail, and C. N. Baxevanis. 2010. A new era in anticancer peptide vaccines. Cancer 116:2071-2080.
137. Perotti, M., N. Ghidoli, R. Altara, R. A. Diotti, N. Clementi, M. D. De, M. Sassi, M. Clementi, R. Burioni, and N. Mancini. 2008. Hepatitis C virus (HCV)-driven stimulation of subfamily-restricted natural IgM antibodies in mixed cryoglobulinemia. Autoimmun. Rev. 7:468-472.
138. Pilla, L., R. Patuzzo, L. Rivoltini, M. Maio, E. Pennacchioli, E. Lamaj, A. Maurichi, S. Massarut, A. Marchiano, C. Santantonio, D. Tosi, F. Arienti, A. Cova, G. Sovena, A. Piris, D. Nonaka, I. Bersani, F. A. Di, M. Luigi, P. K. Srivastava, A. Hoos, M. Santinami, and G. Parmiani. 2006. A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients. Cancer Immunol. Immunother. 55:958-968.
139. Pinilla, C., V. Rubio-Godoy, V. Dutoit, P. Guillaume, R. Simon, Y. Zhao, R. A. Houghten, J. C. Cerottini, P. Romero, and D. Valmori. 2001. Combinatorial peptide libraries as an alternative approach to the identification of ligands for tumor-reactive cytolytic T lymphocytes. Cancer Res. 61:5153-5160.
140. Pleasance, E. D., R. K. Cheetham, P. J. Stephens, D. J. McBride, S. J. Humphray, C. D. Greenman, I. Varela, M. L. Lin, G. R. Ordonez, G. R. Bignell, K. Ye, J. Alipaz, M. J. Bauer, D. Beare, A. Butler, R. J. Carter, L. Chen, A. J. Cox, S. Edkins, P. I. Kokko-Gonzales, N. A. Gormley, R. J. Grocock, C. D. Haudenschild, M. M. Hims, T. James, M. Jia, Z. Kingsbury, C. Leroy, J. Marshall, A. Menzies, L. J. Mudie, Z. Ning, T. Royce, O. B. Schulz-Trieglaff, A. Spiridou, L. A. Stebbings, L. Szajkowski, J. Teague, D. Williamson, L. Chin, M. T. Ross, P. J. Campbell, D. R. Bentley, P. A. Futreal, and M. R. Stratton. 2010. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463:191-196.
141. Prehn, R. T. 1970. Analysis of antigenic heterogeneity within individual 3-methylcholanthrene-induced mouse sarcomas. J. Natl. Cancer Inst. 45:1039-1045.
142. Radtke, I., C. G. Mullighan, M. Ishii, X. Su, J. Cheng, J. Ma, R. Ganti, Z. Cai, S. Goorha, S. B. Pounds, X. Cao, C. Obert, J. Armstrong, J. Zhang, G. Song, R. C. Ribeiro, J. E. Rubnitz, S. C. Raimondi, S. A. Shurtleff, and J. R. Downing. 2009. Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia. Proc. Natl. Acad. Sci. U. S. A. 106:12944-12949.
143. Ragupathi, G. 1996. Carbohydrate antigens as targets for active specific immunotherapy. Cancer Immunol. Immunother. 43:152-157.
144. Ranieri, E., L. S. Kierstead, H. Zarour, J. M. Kirkwood, M. T. Lotze, T. Whiteside, and W. J. Storkus. 2000. Dendritic cell/peptide cancer vaccines: clinical responsiveness and epitope spreading. Immunol. Invest. 29:121-125.
145. Rech, A. J., and R. H. Vonderheide. 2009. Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann. N. Y. Acad. Sci. 1174:99-106.
146. Rivoltini, L., P. Canese, V. Huber, M. Iero, L. Pilla, R. Valenti, S. Fais, F. Lozupone, C. Casati, C. Castelli, and G. Parmiani. 2005. Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control? Expert Opin. Biol. Ther. 5:463-476.
147. Rosenberg, S. A. 2001. Progress in human tumour immunology and immunotherapy. Nature 411:380-384.
148. + T cells in patients with melanoma. J. Immunol. 175:6169-6176.
149. Rosenberg, S. A., J. C. Yang, and N. P. Restifo. 2004. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10:909-915.
150. Rosenberg, S. A., J. C. Yang, S. L. Topalian, D. J. Schwartzentruber, J. S. Weber, D. R. Parkinson, C. A. Seipp, J. H. Einhorn, and D. E. White. 1994. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271:907-913.
151. Rosenberg, S. A., J. R. Yannelli, J. C. Yang, S. L. Topalian, D. J. Schwartzentruber, J. S. Weber, D. R. Parkinson, C. A. Seipp, J. H. Einhorn, and D. E. White. 1994. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl. Cancer Inst. 86:1159-1166.
152. Sakaguchi, S. 2005. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat. Immunol. 6:345-352.
153. Sasada, T., M. Kimura, Y. Yoshida, M. Kanai, and A. Takabayashi. 2003. CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 98:1089-1099. (Pubitemid 37022112)
154. Schmidt, S. M., K. Schag, M. R. Muller, M. M. Weck, S. Appel, L. Kanz, F. Grunebach, and P. Brossart. 2003. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood 102:571-576.
155. Schmollinger, J. C., R. H. Vonderheide, K. M. Hoar, B. Maecker, J. L. Schultze, F. S. Hodi, R. J. Soiffer, K. Jung, M. J. Kuroda, N. L. Letvin, E. A. Greenfield, M. Mihm, J. L. Kutok, and G. Dranoff. 2003. Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction. Proc. Natl. Acad. Sci. U. S. A. 100:3398-3403.
156. Schoenberger, S. P., R. E. Toes, E. I. van der Voort, R. Offringa, and C. J. Melief. 1998. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393:480-483.
157. Schuler, G., B. Schuler-Thurner, and R. M. Steinman. 2003. The use of dendritic cells in cancer immunotherapy. Curr. Opin. Immunol. 15:138-147.
158. Shen, L. S., J. Wang, D. F. Shen, X. L. Yuan, P. Dong, M. X. Li, J. Xue, F. M. Zhang, H. L. Ge, and D. Xu. 2009. CD4(+)CD25(+)CD127(low/-) regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression. Clin. Immunol. 131:109-118.
159. + CTL in vivo with peptide vaccine constructs. J. Immunol. 152:549-556.
160. Simons, J. W., M. A. Carducci, B. Mikhak, M. Lim, B. Biedrzycki, F. Borellini, S. M. Clift, K. M. Hege, D. G. Ando, S. Piantadosi, R. Mulligan, and W. G. Nelson. 2006. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naive prostate cancer. Clin. Cancer Res. 12:3394-3401.
161. Slansky, J. E., F. M. Rattis, L. F. Boyd, T. Fahmy, E. M. Jaffee, J. P. Schneck, D. H. Margulies, and D. M. Pardoll. 2000. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity 13:529-538.
162. Small, E. J., N. Sacks, J. Nemunaitis, W. J. Urba, E. Dula, A. S. Centeno, W. G. Nelson, D. Ando, C. Howard, F. Borellini, M. Nguyen, K. Hege, and J. W. Simons. 2007. Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin. Cancer Res. 13:3883-3891.
163. Sole, X., N. Bonifaci, N. Lopez-Bigas, A. Berenguer, P. Hernandez, O. Reina, C. A. Maxwell, H. Aguilar, A. Urruticoechea, S. de Sanjose, F. Comellas, G. Capella, V. Moreno, and M. A. Pujana. 2009. Biological convergence of cancer signatures. PLoS One 4:e4544.
164. + T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. 115:739-746.
165. Srivastava, P. K., M. K. Callahan, and M. M. Mauri. 2009. Treating human cancers with heat shock protein-peptide complexes: the road ahead. Expert Opin. Biol. Ther. 9:179-186.
166. Srivastava, P. K., A. B. DeLeo, and L. J. Old. 1986. Tumor rejection antigens of chemically induced sarcomas of inbred mice. Proc. Natl. Acad. Sci. U. S. A. 83:3407-3411.
167. Srivastava, P. K., H. Udono, N. E. Blachere, and Z. Li. 1994. Heat shock proteins transfer peptides during antigen processing and CTL priming. Immunogenetics 39:93-98.
168. Stevenson, G. T., E. V. Elliott, and F. K. Stevenson. 1977. Idiotypic determinants on the surface immunoglobulin of neoplastic lymphocytes: a therapeutic target. Fed. Proc. 36:2268-2271.
169. Stratton, M. R., P. J. Campbell, and P. A. Futreal. 2009. The cancer genome. Nature 458:719-724.
170. Syed, A. S., M. D'Antonio, and F. D. Ciccarelli. 2010. Network of Cancer Genes: a web resource to analyze duplicability, orthology and network properties of cancer genes. Nucleic Acids Res. 38:D670-D675.
171. Tamura, Y., P. Peng, K. Liu, M. Daou, and P. K. Srivastava. 1997. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 278:117-120.
172. Testori, A., J. Richards, E. Whitman, G. B. Mann, J. Lutzky, L. Camacho, G. Parmiani, G. Tosti, J. M. Kirkwood, A. Hoos, L. Yuh, R. Gupta, and P. K. Srivastava. 2008. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J. Clin. Oncol. 26:955-962.
173. Thomas, L. 1959. Reactions to homologous tissue antigens in relation to hypersensitivity, p. 529-532. In H. S. Lawrence (ed.), Cellular and humoral aspects of the hypersensitive states. Hoeber-Harper, New York, NY.
174. Toes, R. E., R. J. Blom, R. Offringa, W. M. Kast, and C. J. Melief. 1996. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. J. Immunol. 156:3911-3918.
175. Toes, R. E., R. Offringa, R. J. Blom, C. J. Melief, and W. M. Kast. 1996. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc. Natl. Acad. Sci. U. S. A. 93:7855-7860.
176. Toyokuni, T., B. Dean, S. Cai, D. Boivin, S. Hakomori, and A. K. Singhal. 1994. Synthetic vaccines: synthesis of a dimeric Tn antigen-lipopeptide conjugate that elicits immune responses against Tn-expressing glycoproteins. J. Am. Chem. Soc. 116:395-396.
177. Traversari, C., P. van der Bruggen, I. F. Luescher, C. Lurquin, P. Chomez, A. Van Pel, E. De Plaen, A. Amar-Costesec, and T. Boon. 1992. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J. Exp. Med. 176:1453-1457.
178. Tsang, K. Y., S. Zaremba, C. A. Nieroda, M. Z. Zhu, J. M. Hamilton, and J. Schlom. 1995. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J. Natl. Cancer Inst. 87:982-990.
179. Udono, H., and P. K. Srivastava. 1994. Comparison of tumor-specific immunogenicities of stress-induced proteins gp96, hsp90, and hsp70. J. Immunol. 152:5398-5403.
180. Umano, Y., T. Tsunoda, H. Tanaka, K. Matsuda, H. Yamaue, and H. Tanimura. 2001. Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild-type p53. Br. J. Cancer 84:1052-1057.
181. Valmori, D., J. F. Fonteneau, S. Valitutti, N. Gervois, R. Dunbar, D. Lienard, D. Rimoldi, V. Cerundolo, F. Jotereau, J. C. Cerottini, D. E. Speiser, and P. Romero. 1999. Optimal activation of tumor-reactive T cells by selected antigenic peptide analogues. Int. Immunol. 11:1971-1980.
182. van der Bruggen, P., C. Traversari, P. Chomez, C. Lurquin, E. De Plaen, B. Van den Eynde, A. Knuth, and T. Boon. 1991. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643-1647.
183. Van Doorslaer, K., L. L. Reimers, Y. Y. Studentsov, M. H. Einstein, and R. D. Burk. 2010. Serological response to an HPV16 E7 based therapeutic vaccine in women with high-grade cervical dysplasia. Gynecol. Oncol. 116:208-212.
184. van Maren, W. W., J. F. Jacobs, I. J. de Vries, S. Nierkens, and G. J. Adema. 2008. Toll-like receptor signalling on Tregs: to suppress or not to suppress? Immunology 124:445-452.
185. Vermorken, J. B., A. M. Claessen, H. van Tinteren, H. E. Gall, R. Ezinga, S. Meijer, R. J. Scheper, C. J. Meijer, E. Bloemena, J. H. Ransom, M. G. Hanna, Jr., and H. M. Pinedo. 1999. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 353:345-350.
186. Vogelstein, B., and K. W. Kinzler. 2004. Cancer genes and the pathways they control. Nat. Med. 10:789-799.
187. Vonderheide, R. H., K. S. Anderson, W. C. Hahn, M. O. Butler, J. L. Schultze, and L. M. Nadler. 2001. Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase. Clin. Cancer Res. 7:3343-3348.
188. Vonderheide, R. H., W. C. Hahn, J. L. Schultze, and L. M. Nadler. 1999. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10:673-679.
189. Wang, L., K. Pino-Lagos, V. de Vries, I. Guleria, M. H. Sayegh, and R. J. Noelle. 2008. Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells. Proc. Natl. Acad. Sci. U. S. A. 105:9331-9336.
190. Wang, R. F., E. Appella, Y. Kawakami, X. Kang, and S. A. Rosenberg. 1996. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J. Exp. Med. 184:2207-2216.
191. Wang, Y., A. Rubtsov, R. Heiser, J. White, F. Crawford, P. Marrack, and J. W. Kappler. 2005. Using a baculovirus display library to identify MHC class I mimotopes. Proc. Natl. Acad. Sci. U. S. A. 102:2476-2481.
192. Ward, S., D. Casey, M. C. Labarthe, M. Whelan, A. Dalgleish, H. Pandha, and S. Todryk. 2002. Immunotherapeutic potential of whole tumour cells. Cancer Immunol. Immunother. 51:351-357.
193. + T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin. Cancer Res. 14:178-187.
194. Westerlind, U., A. Hobel, N. Gaidzik, E. Schmitt, and H. Kunz. 2008. Synthetic vaccines consisting of tumor-associated MUC1 glycopeptide antigens and a T-cell epitope for the induction of a highly specific humoral immune response. Angew. Chem. Int. Ed. Engl. 47:7551-7556.
195. Wolf, A. M., D. Wolf, M. Steurer, G. Gastl, E. Gunsilius, and B. Grubeck- Loebenstein. 2003. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin. Cancer Res. 9:606-612.
196. Woo, E. Y., C. S. Chu, T. J. Goletz, K. Schlienger, H. Yeh, G. Coukos, S. C. Rubin, L. R. Kaiser, and C. H. June. 2001. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 61:4766-4772.
197. Wood, C., P. Srivastava, R. Bukowski, L. Lacombe, A. I. Gorelov, S. Gorelov, P. Mulders, H. Zielinski, A. Hoos, F. Teofilovici, L. Isakov, R. Flanigan, R. Figlin, R. Gupta, and B. Escudier. 2008. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 372:145-154.
198. Wood, C. G., and P. Mulders. 2009. Vitespen: a preclinical and clinical review. Future Oncol. 5:763-774.
199. Wood, L. D., D. W. Parsons, S. Jones, J. Lin, T. Sjoblom, R. J. Leary, D. Shen, S. M. Boca, T. Barber, J. Ptak, N. Silliman, S. Szabo, Z. Dezso, V. Ustyanksky, T. Nikolskaya, Y. Nikolsky, R. Karchin, P. A. Wilson, J. S. Kaminker, Z. Zhang, R. Croshaw, J. Willis, D. Dawson, M. Shipitsin, J. K. Willson, S. Sukumar, K. Polyak, B. H. Park, C. L. Pethiyagoda, P. V. Pant, D. G. Ballinger, A. B. Sparks, J. Hartigan, D. R. Smith, E. Suh, N. Papadopoulos, P. Buckhaults, S. D. Markowitz, G. Parmigiani, K. W. Kinzler, V. E. Velculescu, and B. Vogelstein. 2007. The genomic landscapes of human breast and colorectal cancers. Science 318:1108-1113.
200. Wortzel, R. D., C. Philipps, and H. Schreiber. 1983. Multiple tumour-specific antigens expressed on a single tumour cell. Nature 304:165-167.
201. Yuan, X. L., L. Chen, M. X. Li, P. Dong, J. Xue, J. Wang, T. T. Zhang, X. A. Wang, F. M. Zhang, H. L. Ge, L. S. Shen, and D. Xu. 2010. Elevated expression of Foxp3 in tumor-infiltrating Treg cells suppresses T-cell proliferation and contributes to gastric cancer progression in a COX-2-dependent manner. Clin. Immunol. 134:277-288.
202. + T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design. Cancer Res. 62:3630-3635.
203. Zou, W., and N. P. Restifo. 2010. T(H)17 cells in tumour immunity and immunotherapy. Nat. Rev. Immunol. 10:248-256.